CTX-GLS(Cyclophosphamide)

Cyclophosphamide is among the older alkylating agents which has stood the test of time. Its proven benefits in a wide variety of cancers, including haematological malignancies, has made it an irreplaceable component of innumerous chemotherapy regimens. Cyclophosphamide is used in both malignant as well as non-malignant disease.
indications:
malignant disease
for the treatment of malignant lymphomas (stages iii and iv of the ann arbor staging system), hodgkin's disease, lymphocytic lymphoma (nodular or duffse), mixed-cell type lymphoma, histiocytic lymphoma, burkitt's lymphoma
multiple myeloma
leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia, (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration)
mycosis fungoides (advanced disease)
neuroblastoma (disseminated disease)
adenocarcinoma of the ovary
retinoblastoma
carcinoma of the breast
nonmalignant disease
ctx-gls is useful in carefully selected cases of biopsy proven "minimal change" nephrotic syndrome in children but should not be used as primary therapy
in children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, cyclophosphamide may induce a remission
note: cyclophosphamide is not indicated for the nephrotic syndrome in adults or for any other renal disease.
Generic name
strength
standard
type
packing
pack size
cyclophosphamide
200 mg
ip
inj
vial
20 ml
cyclophosphamide
500 mg
ip
inj
vial
50 ml